We are live on
!
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.62B
1-Year Est. Return
138.67%
This Fund
S&P 500
This Quarter
Est. Return
+20.12%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$475M
AUM Growth
+$83M
(+21%)
Cap. Flow
-$6.66M
Cap. Flow
% of AUM
-1.4%
Top 10 Holdings %
Top 10 Hldgs %
73.44%
Holding
42
New
8
Increased
11
Reduced
17
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Natera
NTRA
|
+$37.1M |
| 2 |
United Therapeutics
UTHR
|
+$33.8M |
| 3 |
Sanofi
SNY
|
+$26.7M |
| 4 |
GSK
GSK
|
+$19M |
| 5 |
Celldex Therapeutics
CLDX
|
+$14.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$114M |
| 2 |
Gossamer Bio
GOSS
|
+$24.4M |
| 3 |
Travere Therapeutics
TVTX
|
+$21.1M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$6.45M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$5.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNTA
26
DELISTED
Centessa Pharmaceuticals
CNTA
| $2.94M | 0.62% |
731,521
-26,327
| -3% | -$120K |
|
|
AFMD
27
DELISTED
Affimed
AFMD
| $1.39M | 0.29% |
67,668
-2,435
| -3% | -$67.7K |
|
28
Puma Biotechnology
PBYI
$406M
| $1.33M | 0.28% |
559,769
-20,146
| -3% | -$58.8K |
|
29
Xenon Pharmaceuticals
XENE
$6.32B
| $1.04M | 0.22% |
28,792
-146,208
| -84% | -$5.26M |
|
|
CNTB
30
Connect Biopharma Holdings
CNTB
$135M
| $954K | 0.2% |
739,649
| – | – |
|
31
PUT
Relmada Therapeutics
RLMD
$544M
| $803K | 0.17% |
+300,000
| New | +$8.31M |
|
32
Cabaletta Bio
CABA
$439M
| $343K | 0.07% |
527,805
-18,995
| -3% | -$22.9K |
|
|
TCDA
33
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
| $338K | 0.07% |
+260,000
| New | +$2.84M |
|
|
TCDA
34
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
| $122K | 0.03% |
+97,600
| New | +$1.07M |
|
35
Neurogene
NGNE
$696M
| $77K | 0.02% |
6,018
-217
| -3% | -$4.43K |
|
36
Gyre Therapeutics
GYRE
$662M
| $45K | 0.01% |
12,025
-433
| -3% | -$5.5K |
|
37
CALL
Liquidia Corp
LQDA
$7.67B
| $13K | ﹤0.01% |
+507,700
| New | +$2.85M |
|
38
PUT
Alnylam Pharmaceuticals
ALNY
$36.3B
| – | – |
-50,000
| Closed | -$925K |
|
|
39
CALL
Celldex Therapeutics
CLDX
$2.77B
| – | – |
-246,400
| Closed | -$2.48M |
|
40
Fate Therapeutics
FATE
$281M
| – | – |
-81,064
| Closed | -$2.01M |
|
|
MRUS
41
DELISTED
Merus
MRUS
| – | – |
-103,627
| Closed | -$2.35M |
|
|
KRTX
42
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-38,900
| Closed | -$578K |
|
Similar funds
IPW
WIC
HH
TLFA
KCM
PRA
BW
CC
Kynam Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Kynam Capital Management held 42 positions worth $475M, up 21% from $392M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Kynam Capital Management's Q3 2022 filing shows 8 new, 11 increased, 17 reduced and 5 closed positions. Its largest new stake was United Therapeutics: 151,009 shares worth $31.6M. The largest sale was Global Blood Therapeutics, Inc., an estimated $114M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.
- Kynam Capital Management's largest Q3 2022 buy was United Therapeutics: 151,009 shares worth $31.6M.
- Kynam Capital Management added most to Natera in Q3 2022, an estimated $37.1M increase.
- Kynam Capital Management's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $114M.
- Kynam Capital Management fully exited Merus in Q3 2022, selling an estimated $2.35M.
- Kynam Capital Management's ten largest holdings make up 73% of its $475M portfolio in Q3 2022.
- Kynam Capital Management opened 8 new positions and closed 5 in Q3 2022.
- Kynam Capital Management's portfolio value rose 21% quarter-over-quarter to $475M.
Based on Kynam Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.